flipper, seems that is the new trial with the anti-PD1 immune checkpoint inhibitor (Keytruda) from the statements LP is making.
"we recently opened a novel clinical trial to investigate the safety and efficacy of combining a personalized dendritic cell vaccine with an anti-PD1 immune checkpoint inhibitor, said Dr. Liau. Although we had tested both agents independently in the past, this is the first-in-human trial combining the two approaches in order to harness the immune system against brain cancer"
You would think Merck is in engaged with NWBO at this point....
Market Data 
Markets 
AI
